FcγRIIa and FcγRIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease | Citedby Results | Clinical Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

FcγRIIa and FcγRIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

Clin Cancer Res (2014) 20 (17): 4511–4519.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients

Francesco Sclafani
Sanna Hulkki Wilson
David Cunningham
David Gonzalez De Castro
Eleftheria Kalaitzaki
Ruwaida Begum
Andrew Wotherspoon
Jaume Capdevila
Bengt Glimelius
Susana Roselló
Janet Thomas
Daina Tait
Gina Brown
Jacqui Oates
Ian Chau

International Journal of Cancer (2020) 146 (1): 94.

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis

E K Morgen
H-J Lenz
D J Jonker
D Tu
G Milano
F Graziano
J Zalcberg
C S Karapetis
A Dobrovic
C J O’Callaghan
G Liu

The Pharmacogenomics Journal (2017) 17 (6): 535.

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab

Ayman Madi
David Fisher
Timothy S Maughan
James P Colley
Angela M Meade
Sabine Tejpar
Ben Van den Bosch
Julie Maynard
Vikki Humphreys
Harpreet Wasan
Richard A Adams
Shelley Idziaszczyk
Rebecca Harris
Richard S Kaplan
Jeremy P Cheadle

Journal of Medical Genetics (2017) 54 (8): 567.

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

Sean P. Arlauckas
Christopher S. Garris
Rainer H. Kohler
Maya Kitaoka
Michael F. Cuccarese
Katherine S. Yang
Miles A. Miller
Jonathan C. Carlson
Gordon J. Freeman
Robert M. Anthony
Ralph Weissleder
Mikael J. Pittet

Science Translational Medicine (2017) 9 (389)

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

Francesco Sclafani
Ian Chau
David Cunningham
Andrea Lampis
Jens Claus Hahne
Michele Ghidini
Hazel Lote
Domenico Zito
Josep Tabernero
Bengt Glimelius
Andres Cervantes
Ruwaida Begum
David Gonzalez De Castro
Sanna Hulkki Wilson
Clare Peckitt
Zakaria Eltahir
Andrew Wotherspoon
Diana Tait
Gina Brown
Jacqueline Oates
Chiara Braconi
Nicola Valeri

Carcinogenesis (2016) 37 (9): 852.

miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells

Sofia E. Gomes
André E. S. Simões
Diane M. Pereira
Rui E. Castro
Cecília M. P. Rodrigues
Pedro M. Borralho

Oncotarget (2016) 7 (8): 9368.

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies

John F. Deeken
Hongkun Wang
Deepa Subramaniam
Aiwu Ruth He
Jimmy Hwang
John L. Marshall
Christina E. Urso
Yiru Wang
Corinne Ramos
Kenneth Steadman
Michael J. Pishvaian

Cancer (2015) 121 (10): 1645.